Skip to content

Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01985919
Enrollment
206
Registered
2013-11-18
Start date
2010-02-01
Completion date
2026-07-14
Last updated
2026-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No Restrictions on Diagnosis

Brief summary

This clinical research protocol is intended to allow for bone marrow aspirate/biopsy and blood specimens to be collected for research purposes, specifically allowing subjects the option of sedation during the bone marrow procedure. Samples will be banked for future research related to cancer and other diseases. Researchers hope this protocol will improve the collection of research correlative and translational biopsy specimens for clinical research.

Interventions

OTHERObtaining human tissue for basic research or biospecimen bank

Sponsors

Abramson Cancer Center at Penn Medicine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Planned procedure including a bone marrow aspirate and/or bone marrow biopsy * The procedure is planned for the purpose of obtaining a research specimen (as part of another research study or as part of this stand-alone sample collection protocol.). Procedures with a dual purpose (i.e. to obtain both clinically-indicated specimens and research specimens) are permitted, but procedures to obtain clinical specimens only are not permitted. * All subjects must provide written informed consent for the biopsy procedure, the collection of bone marrow and blood specimens for research purposes and (if planned) the administration of sedation.

Exclusion criteria

* Moderate sedation may not be administrated to subjects with a clinical contraindication to its provision, or if the investigator believes that administration of moderate sedation would constitute under risk to the subject.

Design outcomes

Primary

MeasureTime frame
Number of Adverse Events2 years

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDan Vogl, MD

Abramson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 18, 2026